Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-15 | Ms. Georgeann F. CoucharaSVP of HR | -281,00 | 45,50k | Sale to Issuer | 161,91 | 8,29k | -3,28% |
| 2026-05-01 | Mr. Alan G. SpoonIndependent Director | -1,36k | 139,59k | Derivative Exercise and Sale | 71,88 - 174,67 | 86,89k | - |
| 2026-05-01 | Mr. Alan G. SpoonIndependent Director | 1,94k | 139,45k | Derivative Exercise and Retained Stock | 71,88 | 86,89k | 2,28% |
| 2026-03-01 | Ms. Georgeann F. CoucharaSVP of HR | -113,00 | 23,80k | Sale to Issuer | 210,64 | 8,57k | -1,30% |
| 2026-03-01 | Ms. Julie Sawyer MontgomeryExec. VP of Diagnostics Platform | -1,08k | 227,49k | Sale to Issuer | 210,64 | 6,18k | -14,88% |
| 2026-03-01 | Mr. Christopher Paul RileyExec. VP of Biotechnology Group & CEO of Cytiva | -1,12k | 234,86k | Sale to Issuer | 210,64 | 20,40k | -5,18% |
| 2026-03-01 | Dr. Jose-Carlos Gutierrez-RamosSenior VP & Chief Science Officer | -284,00 | 59,82k | Sale to Issuer | 210,64 | 8,21k | -3,35% |
| 2026-03-01 | Mr. Matthew E. GuginoExec. VP & CFO | -231,00 | 48,66k | Sale to Issuer | 210,64 | 7,53k | -2,98% |
| 2026-03-01 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -118,00 | 24,86k | Sale to Issuer | 210,64 | 4,11k | -2,79% |
| 2026-03-01 | Mr. Christopher M. BoudaVP & CAO | -170,00 | 35,81k | Sale to Issuer | 210,64 | 6,91k | -2,40% |
| 2026-02-27 | Mr. Mitchell P. RalesCo-Founder & Director | -71,65k | 0,00 | Other Disposition | - | 33,76M | -0,21% |
| 2026-02-24 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -189,00 | 39,54k | Sale to Issuer | 209,19 | 4,91k | -3,71% |
| 2026-02-24 | Ms. Georgeann F. CoucharaSVP of HR | -101,00 | 21,13k | Sale to Issuer | 209,19 | 3,94k | -2,50% |
| 2026-02-24 | Mr. Christopher M. BoudaVP & CAO | -235,00 | 49,16k | Sale to Issuer | 209,19 | 6,52k | -3,48% |
| 2026-02-24 | Dr. Jose-Carlos Gutierrez-RamosSenior VP & Chief Science Officer | -344,00 | 71,96k | Sale to Issuer | 209,19 | 7,63k | -4,31% |
| 2026-02-24 | Mr. Christopher Paul RileyExec. VP of Biotechnology Group & CEO of Cytiva | -242,00 | 50,62k | Sale to Issuer | 209,19 | 15,34k | -1,55% |
| 2026-02-24 | Ms. Julie Sawyer MontgomeryExec. VP of Diagnostics Platform | -372,00 | 77,82k | Sale to Issuer | 209,19 | 5,10k | -6,80% |
| 2026-02-19 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -1,32k | 197,24k | Derivative Exercise and Sale | 58,59 - 208,01 | 5,10k | - |
| 2026-02-02 | Mr. Brian W. EllisInsider | -1,25k | 280,17k | Sale to Issuer | 223,42 | 13,30k | -8,62% |
| 2026-02-02 | Dr. Jose-Carlos Gutierrez-RamosSenior VP & Chief Science Officer | -852,00 | 190,35k | Sale to Issuer | 223,42 | 7,98k | -9,65% |
| 2026-02-02 | Mr. Matthew R. McGrewExec. VP | -1,86k | 414,67k | Sale to Issuer | 223,42 | 28,44k | -6,13% |
| 2026-02-02 | Mr. Christopher Paul RileyExec. VP of Biotechnology Group & CEO of Cytiva | -640,00 | 142,99k | Sale to Issuer | 223,42 | 14,54k | -4,22% |
| 2026-02-02 | Mr. Rainer M. BlairPresident, CEO & Director | -7,75k | 1,73M | Sale to Issuer | 223,42 | 70,20k | -9,94% |
| 2025-11-25 | Mr. Mitchell P. RalesCo-Founder & Director | -40,63k | 9,36M | Verkauf | 230,27 - 231,19 | 33,83M | -0,12% |
| 2025-11-25 | Mr. Mitchell P. RalesCo-Founder & Director | -22,03k | 0,00 | Other Disposition | - | 33,87M | -0,06% |
| 2025-11-18 | Ms. Teri L. List-StollIndependent Director | -3,30k | 509,94k | Derivative Exercise and Sale | 71,88 - 226,50 | 23,00 | - |
| 2025-11-15 | Mr. Gregory M. MilosevichExec. VP of Life Sciences Business | -35,00 | 7,74k | Sale to Issuer | 221,21 | 4,42k | -0,79% |
| 2025-11-15 | Mr. R. Bradley GraySVP of Strategic Development | -1,40k | 310,14k | Sale to Issuer | 221,21 | 2,94k | -32,31% |
| 2025-11-15 | Ms. Julie Sawyer MontgomeryExec. VP of Diagnostics Platform | -265,00 | 58,62k | Sale to Issuer | 221,21 | 4,62k | -5,43% |
| 2025-11-11 | Mr. Matthew R. McGrewExec. VP | -16,17k | 2,45M | Derivative Exercise and Sale | 62,85 - 214,62 | 30,28k | - |
| 2025-11-12 | Mr. Brian W. EllisInsider | -21,78k | 3,50M | Derivative Exercise and Sale | 58,59 - 219,23 | 14,55k | - |
| 2025-11-12 | Mr. Mitchell P. RalesCo-Founder & Director | -437,00k | 95,57M | Verkauf | 217,64 - 220,15 | 33,90M | -1,27% |
| 2025-11-10 | Ms. Georgeann F. CoucharaSVP of HR | -4,18k | 510,32k | Derivative Exercise and Sale | 88,24 - 210,44 | 2,63k | - |
| 2025-11-10 | Ms. Georgeann F. CoucharaSVP of HR | -998,00 | 209,89k | Verkauf | 210,31 | 2,63k | -27,55% |
| 2025-10-31 | Mr. Mitchell P. RalesCo-Founder & Director | -600,00k | 129,64M | Verkauf | 215,67 - 217,17 | 34,33M | -1,72% |
| 2025-08-22 | Ms. Teri L. List-StollIndependent Director | -2,78k | 586,32k | Verkauf | 211,06 | 12,00 | -99,57% |
| 2025-07-15 | Dr. Elias Adam ZerhouniIndependent Director | 2,72k | 161,35k | Derivative Exercise and Retained Stock | 59,34 | 15,61k | 21,09% |
| 2025-07-15 | Dr. Elias Adam ZerhouniIndependent Director | -1,21k | 161,43k | Derivative Exercise and Sale | 59,34 - 192,86 | 15,61k | - |
| 2025-07-15 | Mr. John T. SchwietersInsider | 2,72k | 161,35k | Derivative Exercise and Retained Stock | 59,34 | 40,96k | 7,11% |
| 2025-07-15 | Mr. John T. SchwietersInsider | -1,21k | 161,43k | Derivative Exercise and Sale | 59,34 - 192,86 | 40,96k | - |
| 2025-07-15 | Mr. Christopher M. BoudaVP & CAO | -61,00 | 11,76k | Sale to Issuer | 192,86 | 6,27k | -0,96% |
| 2025-07-02 | Ms. Teri L. List-StollIndependent Director | 2,78k | 164,85k | Derivative Exercise and Retained Stock | 59,34 | 2,78k | - |
| 2025-07-02 | Ms. Teri L. List-StollIndependent Director | -1,15k | 164,90k | Derivative Exercise and Sale | 59,34 - 202,73 | 2,78k | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
